Atorvastatin
- CAS NO.:110862-48-1
- Empirical Formula: C33H35FN2O5
- Molecular Weight: 558.64
- EINECS: 214-486-9
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-04-01 21:53:03
What is Atorvastatin?
Definition
ChEBI: Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-).
Clinical Use
Hyperlipidaemia and hypercholesterolaemia
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: concentration possibly increased
by dronedarone.
Antibacterials: azithromycin, erythromycin,
clarithromycin or fusidic acid possibly increased
risk of myopathy - avoid atorvastatin for at least
7 days after fusidic acid stopped; concentration
increased by clarithromycin - do not exceed 20 mg
of atorvastatin1
; avoid with telithromycin; increased
risk of myopathy with daptomycin; concentration
possibly reduced by rifampicin.
Anticoagulants: may transiently reduce anticoagulant
effect of warfarin.
Antifungals: increased risk of myopathy with
itraconazole - do not exceed 40 mg of atorvastatin1
;
increased risk of myopathy with fluconazole,
ketoconazole, posaconazole, voriconazole and
possibly other imidazoles and triazoles - avoid.
Antivirals: increased risk of myopathy with
atazanavir, boceprevir (reduce atorvastatin dose),
and possibly darunavir, fosamprenavir, indinavir,
lopinavir, ritonavir, saquinavir or tipranavir (max
dose of atorvastatin 10 mg); concentration reduced
by efavirenz and possibly etravirine; avoid with
dasabuvir, ombitasvir, paritaprevir and telaprevir;
possible increased risk of myopathy with ledipasvir
- reduce atorvastatin dose; concentration increased
by simeprevir - consider reducing atorvastatin
dose.
Calcium channel blockers: concentration increased
by diltiazem - increased risk of myopathy;
concentration of verapamil increased also possible
increased risk of myopathy - consider reducing
atorvastatin dose.
Ciclosporin: increased risk of myopathy - do not
exceed 10 mg of atorvastatin.1 Cobicistat: reduce atorvastatin dose.
Colchicine: possible increased risk of myopathy.
Grapefruit juice: concentration possibly increased.
Lipid lowering agents: increased risk of myopathy
with fibrates, gemfibrozil (avoid) and nicotinic acid.
Metabolism
Atorvastatin undergoes extensive presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. These products are further metabolised via glucuronidation. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. Atorvastatin is eliminated primarily in bile as active metabolites following hepatic and/or extrahepatic metabolism, but does not appear to undergo significant enterohepatic recirculation.
Properties of Atorvastatin
Boiling point: | 722.2±60.0 °C(Predicted) |
Density | 1.23±0.1 g/cm3(Predicted) |
pka | 4.29±0.10(Predicted) |
Safety information for Atorvastatin
Computed Descriptors for Atorvastatin
New Products
ALUMINIUM IODIDE 100 GM BUFFER CAPSULE PH 7.0 - 10 CAP BUFFER SOLUTION PH 9.5 (BORATE) EZEE BLUE GEL STAINER BORAX CARMINE (GRENACHERS ALCOHOLIC) POTASSIUM IODATE - IODIDE SOLN 0.1 N Dabigatran Acyl-O3-D-Glucuronide Trifluoroacetic Acid Salt Isofolic Acid Dabigatran 2-O-acylglucuronide metabolite Dabigatran Acyl-?-D- glucuronide Trifluroacetic Acid Erythromycin EP Impurity A Desloratidine Related Compound ARelated products of tetrahydrofuran
You may like
-
110862-48-1 ATORVASTATIN 10% DC GRANULES 98%View Details
110862-48-1 -
110862-48-1 98%View Details
110862-48-1 -
Dechloro DesloratadineView Details
-
Dehydro DesloratadineView Details
-
Edoxaban Impurity 57View Details
2089454-69-1 -
Empagliflozin Bromo ImpurityView Details
-
Glycopyrronium Bromide EP Impurity IView Details
1404617-94-2 -
Ipratropium EP Impurity BView Details
58073-59-9